Eli Lilly announced that orforglipron, a once-daily oral GLP-1 receptor agonist, met primary and key secondary endpoints in the Phase 3 ATTAIN-2 trial involving adults with obesity or overweight and type 2 diabetes. At the highest dose, participants lost an average of 10.5% body weight and achieved significant A1C reductions. The data position orforglipron as a competitive oral candidate against injectable GLP-1 drugs, potentially addressing the growing market for obesity and diabetes with improved patient convenience.